VPI
LCTX icon

Value Partners Investments’s Lineage Cell Therapeutics LCTX Stock Holding History

Value Partners Investments’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-150,000
Closed -$366K – 68
2021
Q4 		$366K Buy
150,000
+30,000
+25% +$70.2K 0.03% 65
2021
Q3 		$301K Hold
120,000
– – 0.03% 70
2021
Q2 		$342K Buy
+120,000
New +$311K 0.03% 66

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Value Partners Investments's LCTX Position: Q1 2022 in Review

Value Partners Investments sold out of Lineage Cell Therapeutics (LCTX) in Q1 2022, closing a stake of 150,000 shares — an estimated $366K sold.

Value Partners Investments first reported a position in LCTX in Q2 2021 and held it in 3 quarters. The position peaked at $366K in Q4 2021. 110 funds tracked by Wall St. Rank hold LCTX as of Q1 2022.

  • Value Partners Investments reported no remaining Lineage Cell Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Value Partners Investments sold 150,000 Lineage Cell Therapeutics shares in Q1 2022, an estimated $366K.
  • Value Partners Investments first reported a position in Lineage Cell Therapeutics in Q2 2021 and held it in 3 quarters.
  • Value Partners Investments's Lineage Cell Therapeutics position peaked at $366K in Q4 2021.
  • 110 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2022.

Based on Value Partners Investments's 13F filing for Q1 2022, filed 14 Apr 2022.